Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Phase 2

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
Acute Lymphoblastic Lymphoma

First Posted Date: 2017-04-18

Last Posted Date: 2024-11-26

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 790

Registration Number: NCT03117751

Locations: 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸
St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺
The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

and more 5 locations

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Angioimmunoblastic T-Cell Lymphoma
Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma
Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma
Hepatosplenic T-Cell Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Adult T-Cell Leukemia/Lymphoma
Anaplastic Large Cell Lymphoma, ALK-Negative
Anaplastic Large Cell Lymphoma, ALK-Positive

Interventions: Drug: Brentuximab Vedotin
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Etoposide Phosphate
Other: Laboratory Biomarker Analysis
Drug: Prednisone

First Posted Date: 2017-04-13

Last Posted Date: 2024-02-20

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 48

Registration Number: NCT03113500

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 2 locations

Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: ARN-509
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2017-04-04

Last Posted Date: 2024-01-16

Lead Sponsor: Daniel George, MD

Target Recruit Count: 93

Registration Number: NCT03098836

Locations: 🇺🇸
UNC Lineberger Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
Southeastern Regional, Lumberton, North Carolina, United States
🇺🇸
Spartanburg Regional, Spartanburg, South Carolina, United States

and more 10 locations

A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant

Phase 4

Completed

Conditions: End-stage Renal Disease

Interventions: Biological: Rabbit Anti-thymocyte Immunoglobulin
Drug: Tacrolimus
Drug: Methylprednisolone
Drug: Mycophenolate mofetil
Drug: Mycophenolate Na
Drug: prednisone

First Posted Date: 2017-04-04

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 115

Registration Number: NCT03099122

Locations: 🇨🇳
CHINA, China, China

A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE

Phase 4

Completed

Conditions: Lupus Erythematosus, Systemic
Lupus Erythematosus
Fatigue

Interventions: Drug: RAYOS
Drug: Prednisone

First Posted Date: 2017-04-04

Last Posted Date: 2020-07-08

Lead Sponsor: Ampel BioSolutions, LLC

Target Recruit Count: 62

Registration Number: NCT03098823

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
The Regents of the University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 18 locations

A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Leuprolide Acetate
Drug: Prednisone
Drug: Docetaxel
Drug: Apalutamide

First Posted Date: 2017-03-28

Last Posted Date: 2020-04-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 9

Registration Number: NCT03093272

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Prednisone in Cystic Fibrosis Pulmonary Exacerbations

Phase 3

Completed

Conditions: Cystic Fibrosis Pulmonary Exacerbation

Interventions: Drug: Placebos
Drug: Prednisone

First Posted Date: 2017-03-03

Last Posted Date: 2024-07-01

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 76

Registration Number: NCT03070522

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦
The Governers of The University of Calgary - Alberta Health Services, Calgary, Alberta, Canada
🇨🇦
British Columbia Children's Hospital, Vancouver, British Columbia, Canada

and more 9 locations

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Phase 1

Completed

Conditions: Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma

Interventions: Drug: Venetoclax
Drug: Rituximab
Drug: Etoposide
Drug: Vincristine Sulfate
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Doxorubicin Hydrochloride

First Posted Date: 2017-01-30

Last Posted Date: 2022-08-24

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 31

Registration Number: NCT03036904

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 3 locations